1
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                   FORM 12b-25

                           NOTIFICATION OF LATE FILING

                                                  Commission File Number 0-20791

(Check One)

[X]  Form 10-K and Form 10-KSB        [ ]  Form 11-K

[ ]  Form 20-F      [ ]  Form 10-Q and Form 10-QSB       [ ]  Form N-SAR

Form period ended    December 31, 2000
                  --------------------------------------------------------------

[ ]  Transition Report on Form 10-K and Form 10-KSB

[ ]  Transition Report on Form 20-F

[ ]  Transition Report on Form 11-K

[ ]  Transition Report on Form 10-Q and Form 10-QSB

[ ]  Transition Report on Form N-SAR

For the transition period ended
                                ------------------------------------------------

Read Attached Instruction Sheet Before Preparing Form.  Please Print or Type.

         Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.

         If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates:
                                                       -------------------------

- --------------------------------------------------------------------------------


                                     PART I
                             REGISTRANT INFORMATION

Full name of registrant:   AMARILLO BIOSCIENCES, INC.

Former name if applicable
                          ------------------------------------------------------

Address of principal executive office (Street and Number):  800 West 9th Avenue

City, state and zip code:  Amarillo, Texas  79101


                                    12b25-1
   2

                                     PART II
                             RULE 12b-25(b) AND (c)

         If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate.)

[X]      (a)      The reasons described in reasonable detail in Part III of
                  this form could not be eliminated without unreasonable effort
                  or expense;

[X]      (b)      The subject annual report, semi-annual report, transition
                  report on Form 10-K, 10-KSB, 10-F, 11-K, or Form N-SAR, or
                  portion thereof will be filed on or before the 15th calendar
                  day following the prescribed due date; or the subject
                  quarterly report or transition report on Form 10-Q, 10-QSB, or
                  portion thereof will be filed on or before the fifth calendar
                  day following the prescribed due date; and

[ ]      (c)      The accountant's statement or other exhibit required by Rule
                  12b-25(c) has been attached if applicable.

                                    PART III
                                    NARRATIVE

         State below in reasonable detail the reasons why Form 10-K, 10-KSB,
11-K, 20-F, 10-Q, 10-QSB, N-SAR or the transition report portion thereof could
not be filed within the prescribed time period. (Attach extra sheets if needed.)

         The registrant is a small biotech company that has recently experienced
         a substantial reduction in work force. The registrant currently has
         only one employee familiar with the contents of the Form 10-KSB and the
         procedure for compiling and filing it. That employee is currently ill.

                                     PART IV
                                OTHER INFORMATION

(1)      Name and telephone number of person to contact in regard to this
         notification.

         M. Ben Bateman
         806/468-3321

(2)      Have all other periodic reports required under Section 13 or 15(d) or
the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).

                                                            [X]  Yes    [ ]  No

                                    12b25-2

   3



(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?

                                                            [ ]  Yes    [X]  No

         If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.


                           AMARILLO BIOSCIENCES, INC.
                  --------------------------------------------
                  (Name of Registrant as Specified in Charter)

         Has caused this notification to be signed on its behalf by the
undersigned thereunto duly authorized.

Date:  March 30, 2001         By: /s/ JOSEPH M. CUMMINS
     -----------------------     ---------------------------------------------
                                      Joseph M. Cummins, President and CEO





                                    12b25-3